Yield of Staging Laparoscopy for Incurable Factors in Chinese Patients with Advanced Gastric Cancer

2018 ◽  
Vol 28 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Jun Huang ◽  
Hongliang Luo ◽  
Chengliang Zhou ◽  
Jianjun Zhan ◽  
Xionghui Rao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Staging Laparoscopy ◽  
Chinese Patients

scholarly journals Significance of Staging Laparoscopy for Advanced Gastric Cancer

2000 ◽  
Vol 25 (5) ◽  
pp. 751-756
Author(s):  
Atsushi NASHIMOTO ◽  
Hiroshi YABUSAKI ◽  
Otsuo TANAKA
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Staging Laparoscopy

scholarly journals THE DIAGNOSTIC CAPABILITY AND CLINICAL IMPORTANCE OF STAGING LAPAROSCOPY FOR ADVANCED GASTRIC CANCER

2011 ◽  
Vol 72 (6) ◽  
pp. 1355-1359
Author(s):  
Yoshihisa YAGUCHI ◽  
Hironori TSUJIMOTO ◽  
Yusuke MATSUMOTO ◽  
Kazumichi YOSHIDA ◽  
Risa TAKAHATA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Clinical Importance ◽  
Staging Laparoscopy ◽  
Diagnostic Capability

A UGT1A1 genotype-directed phase II toxicity and efficacy-finding study of irinotecan combined with S-1 as first-line treatment in advanced gastric cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. TPS4154-TPS4154
Author(s):  
Xiaofeng He ◽  
Zedong Du ◽  
Feng Wen ◽  
Pengfei Zhang ◽  
Ruilei Tang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
The Body ◽  
Chinese Patients ◽  
Severe Neutropenia ◽  
High Dose ◽  
Wild Type ◽  
First Line ◽  
Different Doses ◽  
Ugt1a1 Genotype

TPS4154 Background: The best chemotherapy regimen for advanced gastric cancer (AGC) is uncertain, but promising findings have been reported with Irinotecan (IRI) plus S-1. However, IRI can induce severe neutropenia or diarrhea associated with homozygosity of the UGT1A1*28 or UGT1A1*6 alleles. This trial was designed to compare the toxicity and efficacy on different doses of IRI combined with S-1 according to UGT1A1 genotype as first-line chemotherapy in AGC in Chinese patients. Methods: Previously untreated patients with histologically proven gastric or gastroesophageal junction adenocarcinoma, aged between 18 and 75 years with ECOG performance status 0-2 were classified according to UGT1A1 genotype: wild-type (none of *28 or *6 allele); heterozygous (only one of *28 or *6 allele); or homozygous (*28/*28, *6/*6, or double heterozygous for *28 and *6). Patients were randomized (1:1) to receive either low or high dose of IRI given i.v. (90 min) on day 1 in each genotype group. The low and high dose of IRI were 80mg/m2 and 200 mg/m2 in the wild-type group, 80 mg/m2 and 150 mg/m2 in the heterozygous group, 40 mg/m2 and 80 mg/m2 in the homozygous group. S-1 was administered orally at a dose level set on the basis of the body surface area (BSA): 40 (BSA<1.25 m2), 50 (BSA≥1.25 to<1.5 m2 ) or 60 mg (BSA≥1.5 m2) twice a day on day1-7. Courses were repeated every 2 weeks, unless disease progression, unacceptable toxicity or patient refusal. The primary endpoint was to explore the safety and efficacy on different doses of IRI combined with S-1 according to UGT1A1 polymorphism. Based on the frequency of UGT1A1*28 and UGT1A1*6 gene polymorphism in Asian gastrointestinal cancer patients, the chi-square test and fisher exact test were used to evaluate the planned sample size which is 100 in total: 40 for the wild-type, 40 for the heterozygous and 20 for the homozygous group. Until now, 8 patients have been enrolled. Clinical trial information: ChiCTR-OCH-12002472.

Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 35-35 ◽  
Author(s):  
Wenying Deng ◽  
Shukui Qin ◽  
Jin Li ◽  
Lu Wen ◽  
Junsheng Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Advanced Gastric Cancer ◽  
Initial Dose ◽  
Gastroesophageal Junction ◽  
Objective Response ◽  
Progression Free Survival ◽  
Chinese Patients ◽  
Best Response ◽  
Line Setting

35 Background: A fine balance between maintaining efficacy and reducing toxicity is necessary for drug therapies in many cancers. This study seeks to review the data from phase IV clinical trial of Ahead-G201 to help elucidate the optimal initial dose of apatinib in advanced gastric cancer. Methods: Pts data from the Ahead-G201 study at cut-off date of Jul 10, 2017 were extracted to explore the correlation of apatinib initial dose (500 mg vs 850 mg) with safety and clinical efficacy. Results: 864 of eligible pts received apatinib at an initial dose of 500 mg, and 58 pts received at 850 mg. Dose interruption occurred in 258 pts (33.1%) at 500 mg and in 27 pts (46.5%) at 850 mg. For safety, the most common adverse events (AEs) were proteinuria, hypertension and leukocyte decrease in both groups. Moreover, the incidence of all AEs and grade 3-4 AEs in pts at 500 mg was significantly lower than pts at 850 mg (Table). For efficacy, pts at 500 mg achieved an objective response rate (ORR) of 10.8% and a disease control rate (DCR) of 70.6%, at best response, which were 10.3% and 55.2% in pts at 850 mg. Pts at 500 mg got a significantly longer median progression-free survival (mPFS) and median overall survival (mOS) than pts at 850 mg (PFS, 4.6 mos vs 2.2 mos; OS, 6.8 mos vs 4.0 mos). Multivariate analysis indicated that apatinib treatment at an initial dose of 500 mg was significantly associated with longer mOS in advanced gastric cancer pts (6.8 mos vs 4.0 mos: hazard ratio, 0.5; 95%CI, 0.3 to 0.8), compared to initial dose of 850 mg. Conclusions: Compared to receiving apatinib at initial dose of 850mg, oral administration of apatinib starting from 500 mg seemed to bring more clinical benefit for patients with advanced gastric cancer, whilst with lower toxicities. Clinical trial information: NCT02426034. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document